Diabetes drug Byetta shows no increase in CV risk
This article was originally published in Scrip
Lilly/Amylin's injectable type 2 diabetes drug Byetta (exenatide) shows no increase in cardiovascular risk, the companies concluded after performing a meta-analysis across their clinical trials database of the first-in-class GLP-1 analogue.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.